Novartis' Zelnorm Efficacy Endpoint To Be Debated By FDA Advisory Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis believes the endpoint captures qualitative aspects of a patient's chronic constipation. The agency also questioned whether the patients studied represent the indicated population.